OBJECTIVES: To define resources and procedures to set the direct medical costs of treatment of metastatic breast cancer (MBC) after anthracyclines and taxanes failure from the Mexican public health system perspective. METHODS: The unitary costs of chemotherapy, surgery, radiotherapy and hormonal therapy were obtained trough quantification the consumption of health care resource reported in 587 clinical files of patients with advanced breast cancer patients after failure to anthracyclines and taxanes with at least two years follow-up treated at three tertiary public hospitals in Mexico: Hospital de Oncología del Centro Médico Siglo XXI del Instituto Mexicano del Seguro Social (SigloXXI) (47%), Instituto Nacional de Cancerología (INCAN) (42%) and Centro Universitario contra el Cáncer (CUCC) (11%). All costs (drugs, services and procedures) were obtained from institutional sources and expressed in 2009 US$. RESULTS: The mean unitary cost of surgery at the SigloXXI (n = 26) is US$2177.31 ($1658.31-$2696.31), at the CUCC (n = 16) US$3060.14 ($2548.68- $3571.60), and at the INCan (n = 106) US$2288.36 ($1945.56-$2631.16). The radiotherapy (at least 5 sessions) at the SigloXXI (n = 133) is US$755.90 ($696.59- $815.20), CUCC (n = 31) US$910.28 ($728.20-$1092.36), INCan (n = 136) US$1128.13 ($1004.87-$1251.40). The hormonotherapy cost (at least 3 months) is SigloXXI (n = 107) US$1640.19 ($1154.73-$2125.64), CUCC (n = 30) US$932.40 ($528.49-$1336.31), INCan (n = 102) US$1887.09 ($1396.56-$2377.62). The mean chemotherapy cost (all regimens included for at least 3 cycles) at the SigloXXI (n = 213) US$9278.98 ($8097.55-$10,460.42), CUCC (n = 43) US$6174.23 ($1962.75- $10,385.71), INCan (n = 200) US$8212.42 ($6876.50-$9548.34). CONCLUSIONS: The treatment costs vary widely within every center, as result of the clinical practice variability, but seem consistent between centers included in this analysis with no significant statistical differences.
Juarez–Garcia, A., Vargas-Valencia, J., Martínez-Fonseca, J., Uc-Coyoc, R., Bargalló-Rocha, E., Hernández-Rivera, G., & Gómez-Roel, X. (2010). CN3 DIRECT MEDICAL COSTS OF TREATMENT OF METASTATIC BREAST CANCER AFTER ANTHRACYCLINES AND TAXANES FAILURE FROM THE MEXICAN PUBLIC HEALTH SYSTEM PERSPECTIVE. Value in Health, 13(3), A6. https://doi.org/10.1016/s1098-3015(10)72011-8